Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma

Background: This study assesses the feasibility of producing hyperimmune anti-COVID-19 intravenously administrable immunoglobulin (C-IVIG) from pooled convalescent plasma (PCP) to provide a safe and effective passive immunization treatment option for COVID-19. Materials & methods: PCP was fractionated by modified caprylic acid precipitation followed by ultrafiltration/diafiltration to produce hyperimmune C-IVIG. Results: In C-IVIG, the mean SARS-CoV-2 antibody level was found to be threefold (104 +/- 30 cut-off index) that of the PCP (36 +/- 8.5 cut-off index) and mean protein concentration was found to be 46 +/- 3.7 g/l, comprised of 89.5% immunoglobulins. Conclusion: The current method of producing C-IVIG is feasible as it uses locally available PCP and simpler technology and yields a high titer of SARS-CoV-2 antibody. The safety and efficacy of C-IVIG will be evaluated in a registered clinical trial (NCT 04521309).

Automated summary

This study successfully produced hyperimmune anti-COVID-19 intravenously administrable immunoglobulin (C-IVIG) with high titers of SARS-CoV-2 antibody using simple technology and locally available pooled convalescent plasma. The safety and efficacy of C-IVIG will be evaluated in a registered clinical trial.